TOP RATED NATIONAL CLASS ACTION LAW FIRM
  • HOME
  • ABOUT
    • AWARDS, HONORS & ACCOLADES
  • Class Actions
    • Disability Class Action
    • DATA PRIVACY
    • WAUPACA
    • APPLE WATCH
    • First American Data Breach
    • ZOOM FACEBOOK SHARING
    • DraftKings And FanDuel Lawsuits - DraftKings Arbitration
    • Capital One
    • ParaGard IUD
    • Ethicon Surgical Staples
    • Bard Mesh
    • Wage & Hour Class Action Investigation
  • MASS TORTS
    • PARAQUAT
    • Toxic Infant Formula
    • TALCOM POWDER
    • SUNSCREEN RECALL
    • Poppy Seed Tea Lawsuit
    • AFFF Firefighting Foam
    • Philips CPAP Machine
    • Metaverse
    • T-Mobile
  • DEFECTIVE PRODUCTS
    • Baby Formula Recall
    • Abbott Baby Formula Recall
    • Similac Recall
    • EleCare
    • Infant Formula Recall
    • Alimentum
    • Instant Pot
    • Avaulta Mesh
    • One-Wheel Skateboard
    • Bobby Pillow
    • Personal Heater Recalls
    • Exactech Optetrak Recall
    • Cottonelle Flushable Wipes
    • Takata Airbag
  • DANGEROUS DRUGS
    • ELMIR0N
    • Belviq
    • ZANTAC
    • Xeljanz
    • Valsartan
    • Lamictal
    • Singulair
    • TDF Lawsuit
  • SECURITIES FRAUD
    • Marithon Digital
    • Revance Therapeutics Inc.
    • Bumble Inc.
    • SunPower
    • PayPal
    • Affirm Holdings
    • Cerence
    • Cabaletta Bio, Inc.
    • Sleep Number
    • Aurinia Pharmaceuticals Inc.
    • Stronghold Digital Mining
    • Playstudios, Inc.
    • Innovative Industrial Properties
    • Natera, Inc.
    • Riskified Ltd.
  • Whistleblower
  • RESOURCE CENTER
  • Blog
  • Contact
  • DISCLAIMER
    • PRIVACY NOTICE
  • HOME
  • ABOUT
    • AWARDS, HONORS & ACCOLADES
  • Class Actions
    • Disability Class Action
    • DATA PRIVACY
    • WAUPACA
    • APPLE WATCH
    • First American Data Breach
    • ZOOM FACEBOOK SHARING
    • DraftKings And FanDuel Lawsuits - DraftKings Arbitration
    • Capital One
    • ParaGard IUD
    • Ethicon Surgical Staples
    • Bard Mesh
    • Wage & Hour Class Action Investigation
  • MASS TORTS
    • PARAQUAT
    • Toxic Infant Formula
    • TALCOM POWDER
    • SUNSCREEN RECALL
    • Poppy Seed Tea Lawsuit
    • AFFF Firefighting Foam
    • Philips CPAP Machine
    • Metaverse
    • T-Mobile
  • DEFECTIVE PRODUCTS
    • Baby Formula Recall
    • Abbott Baby Formula Recall
    • Similac Recall
    • EleCare
    • Infant Formula Recall
    • Alimentum
    • Instant Pot
    • Avaulta Mesh
    • One-Wheel Skateboard
    • Bobby Pillow
    • Personal Heater Recalls
    • Exactech Optetrak Recall
    • Cottonelle Flushable Wipes
    • Takata Airbag
  • DANGEROUS DRUGS
    • ELMIR0N
    • Belviq
    • ZANTAC
    • Xeljanz
    • Valsartan
    • Lamictal
    • Singulair
    • TDF Lawsuit
  • SECURITIES FRAUD
    • Marithon Digital
    • Revance Therapeutics Inc.
    • Bumble Inc.
    • SunPower
    • PayPal
    • Affirm Holdings
    • Cerence
    • Cabaletta Bio, Inc.
    • Sleep Number
    • Aurinia Pharmaceuticals Inc.
    • Stronghold Digital Mining
    • Playstudios, Inc.
    • Innovative Industrial Properties
    • Natera, Inc.
    • Riskified Ltd.
  • Whistleblower
  • RESOURCE CENTER
  • Blog
  • Contact
  • DISCLAIMER
    • PRIVACY NOTICE

Cabaletta Bio, Inc. Class Action Lawsuit

Company Name:              Cabaletta Bio, Inc.
Stock Symbol:                   CABA
Class Period:                     October 24, 2019 to December 13, 2021
Motion Deadline:             April 29, 2022
Court:                                Eastern District of Pennsylvania

Investor who suffered losses in Cabaletta Bio Files Cabaletta Bio Class Action Lawsuit

If you suffered losses in Cabaleta Bio stock, call a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit

Investor Files Cabbalatta Bio Class Action Lawsuit

Picture of womenCall a Cabaletta Lawyer about a Cabaletta Bio Class Action Lawsuit
The Cabaletta Bio, Inc. class action lawsuit seeks to represent purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio’s initial public offering conducted on or about October 24, 2019 (the “IPO”); and/or (b) securities between October 24, 2019 and December 13, 2021, inclusive (the “Class Period”).  Commenced on February 28, 2022, the Cabaletta Bio class action lawsuit – captioned Patterson v. Cabaletta Bio, Inc., No. 22-cv-00737 (E.D. Pa.) charges Cabaletta Bio as well as certain of its top executives and directors with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934. If you have questions, contact Cabaletta Bio Lawyer Timothy L. Miles.

If you suffered losses in Cabaletta Bio and wish to serve as lead plaintiff of the Cabaletta Bio class action lawsuit, please provide your information by submitting the form below.  You can also contact Cabaletta Bio Lawyer Timothy L. Miles  by calling 855/846-6529 or via e-mail at tmiles@tmileslaw.com.  Lead plaintiff motions for the Cabaletta Bio class action lawsuit must be filed with the court no later than April 29, 2022.   If you have questions, or need any additional information, contact Cabaletta Bio Lawyer Timothy L. Miles.

Allegations in Cabaletta Bio Class Action Lawsuit

Cabaletta Bio’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris (the “Phase 1 Clinical Trial”), an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.  Pursuant to its IPO, Cabaletta Bio sold approximately 6.8 million shares of common stock priced at $11.00 per share, for approximate proceeds of $69.5 million to Cabaletta Bio after applicable underwriting discounts and commissions, and before expenses.

The Cabaletta Bio class action lawsuit alleges that the IPO’s offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as Cabaletta Bio had represented to investors; (iii) therefore, Cabaletta Bio had overstated DSG3-CAART’s clinical and/or commercial prospects; and (iv) as a result, Cabaletta Bio’s public statements were materially false and misleading at all relevant times.

On December 14, 2021, Cabaletta Bio issued a press release “report[ing] top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV).”  Among other results, Cabaletta Bio reported that two cohort participants had “disease activity scores . . . that worsened . . . after DSG3-CAART infusion” and thus “reduced or discontinued selected systemic therapies prior to DSG3-CAART infusion, as required by the protocol”, while another participant “subsequently received systemic medication to improve disease activity after DSG3-CAART infusion.”  On this news, Cabaletta Bio’s stock price fell by more than 73%, damaging investors.

As of the time the Cabaletta Bio class action lawsuit was filed, the price of Cabaletta Bio common stock continues to trade below the $11.00 per share IPO price.  If you suffered losses in Cabaletta Bio, contact ​Cabaletta Bio Lawyer Timothy L. Miles about the ​Cabaletta Bio, Inc. Class Action Lawsuit.

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Cabaletta Bio: (a) common stock pursuant and/or traceable to the offering documents issued in connection with the IPO, and/or (b) securities during the Class Period to seek appointment as lead plaintiff in the Cabaletta Bio class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Cabaletta Bio, contact Cabaletta Bio Lawyer Timothy L. Miles for a free case evaluation about a Cabaletta Bio Class Action Lawsuit. 

Call a Cabaletta Bio Lawyer About a Cabaletta Bio Class Action Lawsuit

​We have extensive experience in securities fraud class and other class actions.  If you, suffered losses in Cabaletta Bio, fill out our case evaluation form right away and see what an Cabaletta Bio Lawyer can do for you and if you have a case for a Cabaletta Bio Class Action Lawsuit because you suffered losses in Cabaletta Bio.
Picture of Cabaletta Bio
If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit

    CONTACT US FOR A FREE CABALETTA BIO CLASS ACTION LAWSUIT CASE EVALUATION 

Submit
ATTENTION: CABALETTA BIO CLASS ACTION LAWSUIT
If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer​
​for free about a Cabaletta Bio class action lawsuit today. We are here to help.
Cabaletta Bio Lawyer
​855-Tim-MLaw (855) 846-8529
tmiles@timmileslaw.com
If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer today for a free case evaluation about a Cabaletta Bio Class Action Lawsuit.
FREE CASE EVALUATION
Call today for a free, no-obligation case evaluation with a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit.

Hours of Operation

Mon - Fri:  24/7
Sat - Sun:   24/7

Contact Information

Phone:          (855) 846-6529
Email:            tmiles@timmileslaw.com
​
​Website:        www.classactionlawyertn.com

Address:        109 Summit Ridge Ct.
                       Nashville, TN 37219
                       (855) Tim-MLaw (855-846-6529)
 (c) Timmileslaw.com | All Right Reserved 
Tim miles Law Office | Class Actions | Mass Torts